Eplerenone and Clinical Outcomes in Heart Failure: A Comparative Analysis

  • Sabah Hadi Sachet Cardiologist and Director of Maysan Center for Cardiac Diseases and Surgery, Iraq

Abstract

Background: Mineralocorticoid receptor antagonism is an established component of evidence-based heart-failure management, but its effects on cardiac function, congestion biomarkers, functional capacity, hospitalization, mortality, and laboratory safety must be interpreted within the context of the underlying study design. This manuscript demonstrates how a structured synthetic dataset can be analysed across these domains without implying that the results are observed clinical evidence.


Methods: The workbook contained 160 synthetic participants, evenly divided between an Eplerenone group (n=80) and a Control group (n=80). Variables included pre/post ejection fraction (EF), BNP, six-minute walk distance, blood pressure, heart rate, creatinine, potassium, NYHA class, all-cause and cardiac hospitalizations, cardiac death, all-cause death, event timing, and follow-up duration. Descriptive comparisons were calculated from the supplied workbook after a quality audit.


Results: In the synthetic illustration, mean EF change was 3.91 percentage points with Eplerenone versus 1.08 with Control. Mean BNP reduction was 25.16% versus 3.42%, and mean six-minute walk improvement was 48.96 versus 5.97 m. All-cause hospitalization occurred in 12/80 (15.00%) versus 21/80 (26.25%); cardiac hospitalization in 8/80 (10.00%) versus 18/80 (22.50%). Cardiac death was recorded in 0 Eplerenone participants and 2 Controls; all-cause death was recorded in 1 (1.25%) and 5 (6.25%), respectively. These figures are descriptive properties of the simulation and do not estimate a real treatment effect.


Conclusion: The workbook supports a complete, reproducible analysis framework for EF, BNP, exercise capacity, hospitalization, mortality, and safety monitoring. It does not support causal inference or claims of eplerenone efficacy. A publishable clinical manuscript would require source-verified observations, a prespecified protocol, ethics oversight, and an appropriate inferential analysis.


Keywords: Eplerenone; mineralocorticoid receptor antagonist; heart failure; ejection fraction; hospitalization; cardiac death; all-cause mortality; BNP; potassium; synthetic dataset.

Published
2026-11-16
How to Cite
SACHET, Sabah Hadi. Eplerenone and Clinical Outcomes in Heart Failure: A Comparative Analysis. NIU Journal of Health Sciences, [S.l.], v. 12, n. 3, p. 91-97, nov. 2026. ISSN 3136-6457. Available at: <https://niujournals.ac.ug/ojs/index.php/NIUJHS/article/view/2777>. Date accessed: 22 nov. 2026. doi: https://doi.org/10.58709/niujhs.v12i3.2777.